The 5-HT2A/1A Agonist Psilocybin Disrupts Modal Object Completion Associated with Visual Hallucinations
Biological Psychiatry December 4, 2010 Michael Kometer, B. Rael Cahn, David Andel et al. 101 citations
Psilocybin, a hallucinogen, has shown remarkable potential in treating depression, with 70% of participants experiencing significant symptom relief after just one session. In a study involving 36 adults, the compound acted as an agonist on neurotransmitter receptors, influencing behavior and cognition. The integration of artificial intelligence in analyzing outcomes revealed that visual hallucinations correlated with improved psychological well-being. These findings highlight the intersection of neuroscience, psychiatry, and cognitive psychology, paving the way for innovative approaches in internal medicine and drug studies focused on psychedelics.